AMH Fertility Tests: What This Biomarker Can Actually Tell You

AMH fertility tests are increasingly marketed as a way to clarify reproductive potential. Yet the number on the report is frequently asked to answer a question it was not designed to address: whether someone will conceive naturally, either now or years from now.

New Australian research found that primary-care requests for anti-Müllerian hormone testing rose more than 13-fold from 2011 to 2021. That growth sits beside a crucial evidence gap. AMH is a clinically useful biomarker of ovarian reserve, particularly in fertility treatment, but it is not a reliable standalone predictor of natural pregnancy. The distinction is a useful case study in how women’s biomarkers can become misleading when measurement is confused with prediction.

What AMH fertility tests measure

Anti-Müllerian hormone is produced by cells surrounding small, developing follicles in the ovaries. A blood measurement provides an indirect estimate of the remaining follicle pool, often described as ovarian reserve. AMH generally declines with age, although levels vary considerably among women of the same age.

Compared with some reproductive hormones, AMH changes less across the menstrual cycle, so testing can often be performed on different cycle days. That convenience does not make it a complete measure of reproductive health. Results can vary by laboratory assay, and interpretation may be affected by hormonal contraception, polycystic ovary syndrome, ovarian surgery and some medical treatments.

A higher result usually suggests that more follicles may respond during ovarian stimulation. A lower result suggests a smaller expected response. Neither result directly measures egg quality, whether ovulation is occurring consistently, whether the fallopian tubes are open, sperm factors or whether an embryo will implant.

Age remains one of the strongest population-level indicators of egg quality because chromosomal abnormalities become more common over time. AMH and age therefore describe different aspects of reproductive biology. Combining them may inform treatment planning, but neither provides certainty for an individual.

Ovarian reserve is not the same as natural fertility

Natural conception depends on a chain of events rather than one laboratory value. Ovulation, timing, egg and sperm quality, tubal function, the uterine environment and underlying health conditions can all affect the outcome. A biomarker representing follicle quantity cannot integrate that entire system.

This explains why a low AMH result does not mean natural pregnancy is impossible. Someone may have fewer recruitable follicles yet still ovulate an egg capable of fertilisation. Conversely, a high AMH result does not guarantee conception or protect against age-related changes in egg quality. Very high levels can also occur in polycystic ovary syndrome, where ovulation may be irregular.

The Australian findings matter because testing outside a clearly defined clinical question can create false reassurance or disproportionate alarm. A result presented as a fertility score may influence decisions about relationships, contraception, egg freezing or the timing of pregnancy without supporting that level of precision.

Population associations should also be separated from individual forecasts. Average AMH patterns can help researchers describe reproductive ageing, but broad trends cannot state exactly how long one woman will remain fertile or how quickly she will conceive.

When AMH is clinically useful

AMH has an established role in assisted reproduction. Fertility specialists may use it alongside age, an ultrasound antral follicle count, medical history and previous treatment response to estimate how the ovaries could respond to stimulation. This can help inform medication dosing and discussions about the likely number of eggs retrieved.

That role is relevant to emerging treatment research in polycystic ovary syndrome. A recent randomised trial reported that a dapagliflozin-metformin combination improved measures of oocyte quality and reproductive outcomes among patients with PCOS undergoing IVF or ICSI. The finding is potentially important, but it concerns a specific diagnosed population receiving assisted reproduction. It does not turn AMH or any other single marker into a general predictor of conception, and the treatment approach requires further evaluation before broad use.

AMH may also contribute to an assessment when periods are irregular, there is a family history of early menopause, or ovarian surgery, chemotherapy or another condition may have affected ovarian reserve. Even then, it belongs within a wider evaluation. Menstrual history, ultrasound findings and other laboratory tests may change the interpretation.

Using AMH to predict the precise timing of menopause is similarly limited. Lower levels broadly accompany reproductive ageing, but available tests cannot reliably identify the exact age at which an individual will reach menopause.

Biomarkers need context across the lifespan

The limits of AMH have wider relevance because reproductive milestones are increasingly being studied as signals of later health. Recent research linked earlier menopause with faster brain ageing and an earlier Alzheimer’s diagnosis. This is an association, not proof that early menopause directly causes neurodegeneration. Genetics, cardiovascular health, smoking, socioeconomic conditions, medical or surgical menopause and hormone exposure may all contribute.

Even so, age at menopause can be valuable clinical context. It may prompt a broader discussion of bone, cardiovascular and cognitive health, particularly when menopause occurs before age 45 and especially before age 40. The same principle applies to AMH: a biomarker becomes useful when tied to a specific question and interpreted alongside symptoms, age, history and other measurements.

No isolated number captures reproductive capacity or future health. Biomarkers are most informative as one layer in a longitudinal record rather than a verdict delivered at a single moment.

Making reproductive signals more readable

Before AMH testing, the most useful question is what decision the result is expected to inform. If the concern is difficulty conceiving, cycle irregularity or possible early ovarian insufficiency, a broader clinical assessment is more informative than an online test interpreted alone. If pregnancy is being attempted, age and duration of trying remain important in deciding when to seek evaluation.

Cycle length, bleeding patterns, ovulation signs, energy and relevant symptoms only become readable when they are logged consistently over weeks. This is the kind of pattern Tulsy is built to surface, while laboratory biomarkers retain their proper clinical context.

Sources: Medical Xpress, Nature.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.